ARK Genomic ETF (ARKG) Stock
PCQ · ARKG
53.12
Fundamentals
Market cap
$2.76B
Price / Earnings ratio
0.0x
Price / Sales ratio
N/A
Price / Book ratio
N/A
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
N/A
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

InvestorPlace
3 Analysts, 3 Trades to Make Today
NeutralARKGSeptember 22, 2026
InvestorPlaceNeutral
3 Analysts, 3 Trades to Make Today
ARKG

Stocktwits
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing
NeutralARKGSeptember 8, 2026
StocktwitsNeutral
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing
ARKG

Zacks Investment Research
Best-Performing ETF Areas of August
NeutralARKGSeptember 1, 2026
Zacks Investment ResearchNeutral
Best-Performing ETF Areas of August
ARKG

Stocktwits
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
NeutralARKGAugust 27, 2026
StocktwitsNeutral
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
ARKG
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

InvestorPlace
3 Analysts, 3 Trades to Make Today
NeutralARKGSeptember 22, 2026
InvestorPlaceNeutral
3 Analysts, 3 Trades to Make Today
ARKG

Stocktwits
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing
NeutralARKGSeptember 8, 2026
StocktwitsNeutral
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing
ARKG

Zacks Investment Research
Best-Performing ETF Areas of August
NeutralARKGSeptember 1, 2026
Zacks Investment ResearchNeutral
Best-Performing ETF Areas of August
ARKG

Stocktwits
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
NeutralARKGAugust 27, 2026
StocktwitsNeutral
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
ARKG

Stocktwits
CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
NeutralARKGAugust 24, 2026
StocktwitsNeutral
CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
ARKG

Stocktwits
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
NeutralARKGAugust 20, 2026
StocktwitsNeutral
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
ARKG

24/7 Wall Street
ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?
NeutralARKGJuly 21, 2026
24/7 Wall StreetNeutral
ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?
ARKG

Stocktwits
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders
NeutralARKGJuly 20, 2026
StocktwitsNeutral
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders
ARKG

Zacks Investment Research
Best ETF Areas of June
NeutralARKGJuly 6, 2026
Zacks Investment ResearchNeutral
Best ETF Areas of June
ARKG

Stocktwits
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise
NeutralARKGJune 24, 2026
StocktwitsNeutral
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise
ARKG
About ARK Genomic ETF
Companies within ARK Genomic Revolution Multi-Sector ETF (ARKG) are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry.
Fundamentals
Valuation
Market cap$2.76B
Price-to-sales ratioN/A
Price-to-book valueN/A
Price-earnings ratio0.00
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per ShareN/A
Income Statement
Average volume4,278,246
EBITDAN/A
1 year high (52w)$53.71
1 year low (52w)$24.60
Dividend
Ex dividend dateN/A
Dividend amountN/A
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.2 | +0.3 | -18.2 | +1.3 | ||||||||
| 2022 | -21.4 | -4.7 | -3.3 | -29.2 | -9.8 | +1.1 | +11.7 | -2.4 | -8.0 | +1.7 | -4.9 | -13.7 |
| 2023 | +22.1 | -12.0 | +0.2 | -2.7 | +8.3 | +4.7 | +11.9 | -12.9 | -14.6 | -14.6 | +19.5 | +13.0 |
| 2024 | -13.1 | +8.5 | -9.1 | -17.8 | +2.2 | -6.4 | +16.0 | +1.3 | +1.9 | -6.9 | +8.3 | -11.8 |
| 2025 | +9.7 | -7.3 | -10.3 | +8.9 | -3.8 | +12.5 | -1.4 | +4.9 | +12.0 | +7.9 | +1.7 | -2.9 |
| 2026 | +4.3 | -2.1 | -11.7 | +10.3 | +14.3 | +21.0 | -9.5 | +19.2 | +13.9 |



